Severe acute respiratory syndrome-related coronavirus

PrecisionLife Identifies 68 Genes Associated With High Risk of Severe COVID-19, Suggesting Opportunities for Genomic Biomarkers and New Treatment Options

Retrieved on: 
Thursday, June 25, 2020
Branches of biology, Medicine, Biology, Severe acute respiratory syndrome-related coronavirus, Epistasis, Severe acute respiratory syndrome, Biomarker, Sjögren syndrome, Genome-wide association study, Calcium in biology, Vaccine

Prior to an effective and widely available vaccine, PrecisionLife's insights may help to identify patients who are at greatest risk of developing the most severe forms of COVID-19.

Key Points: 
  • Prior to an effective and widely available vaccine, PrecisionLife's insights may help to identify patients who are at greatest risk of developing the most severe forms of COVID-19.
  • The study has overcome this barrier by evaluating combinations of genetic features, which is not possible with existing GWAS approaches.
  • Using a combinatorial (high-order epistasis) analysis approach, PrecisionLife identified 68 protein-coding genes that were highly associated with severe COVID-19, nine of which have been previously linked to differential response to SARS-CoV-2.
  • This pathway is largely driven by calcium ion activation, which is a known serum biomarker associated with severe COVID-19 and ARDS.

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Sorrento Therapeutics, Carnival Corporation, Wells Fargo, and Hebron Technology and Encourages Investors to Contact the Firm

Retrieved on: 
Wednesday, June 24, 2020
Zoonoses, Severe acute respiratory syndrome-related coronavirus, Severe acute respiratory syndrome, Virus, Medicine, Epidemiology, Health

On May 15, 2020, Sorrento announced that it had discovered an antibody that had demonstrated 100% inhibition of SARS-CoV-2 virus infection.

Key Points: 
  • On May 15, 2020, Sorrento announced that it had discovered an antibody that had demonstrated 100% inhibition of SARS-CoV-2 virus infection.
  • On that same day, Defendant Henry Ji, founder and Chief Executive Officer of Sorrento referred to Sorrentos breakthrough as a cure.
  • On this news, Sorrento shares closed at $5.70 per share on May 20, 2020, representing a decline of $4.30, or 43.0%, from the Class Period high.
  • For more information on the Hebron Technology class action go to: https://bespc.com/HEBT
    About Bragar Eagel & Squire, P.C.

ERBA Mannheim Launches CE Marked COVID-19 IgM Antibody ELISA

Retrieved on: 
Wednesday, June 24, 2020
Medical specialties, Branches of biology, Medicine, Glycoproteins, Immunology, Antibodies, Immunologic tests, Immunoglobulin M, ELISA, Severe acute respiratory syndrome-related coronavirus, Viral diseases, Seroconversion

LONDON, June 24, 2020 /PRNewswire/ --In response to the ongoing COVID-19 pandemic, Erba Mannheim today launched the ErbaLisa COVID-19 IgM ELISA kit for detection of IgM antibodies to SARS-CoV-2.

Key Points: 
  • LONDON, June 24, 2020 /PRNewswire/ --In response to the ongoing COVID-19 pandemic, Erba Mannheim today launched the ErbaLisa COVID-19 IgM ELISA kit for detection of IgM antibodies to SARS-CoV-2.
  • IgM antibodies are produced first and detectable during disease onset, so using the new assay in combination with Erba's existing ErbaLisa COVID-19 IgG ELISA will detect both early and late phases of the immune response.
  • With full CE certification, products are now available through Erba's global distribution network, including in the USA.
  • Erba Mannheim is a global company focused on delivering innovative, affordable and sustainable healthcare solutions to developing nations.

ERBA Mannheim Launches CE Marked COVID-19 IgM Antibody ELISA

Retrieved on: 
Wednesday, June 24, 2020
Medical specialties, Branches of biology, Medicine, Glycoproteins, Immunology, Antibodies, Immunologic tests, Immunoglobulin M, ELISA, Severe acute respiratory syndrome-related coronavirus, Viral diseases, Seroconversion

LONDON, June 24, 2020 /PRNewswire/ --In response to the ongoing COVID-19 pandemic, Erba Mannheim today launched the ErbaLisa COVID-19 IgM ELISA kit for detection of IgM antibodies to SARS-CoV-2.

Key Points: 
  • LONDON, June 24, 2020 /PRNewswire/ --In response to the ongoing COVID-19 pandemic, Erba Mannheim today launched the ErbaLisa COVID-19 IgM ELISA kit for detection of IgM antibodies to SARS-CoV-2.
  • IgM antibodies are produced first and detectable during disease onset, so using the new assay in combination with Erba's existing ErbaLisa COVID-19 IgG ELISA will detect both early and late phases of the immune response.
  • With full CE certification, products are now available through Erba's global distribution network, including in the USA.
  • Erba Mannheim is a global company focused on delivering innovative, affordable and sustainable healthcare solutions to developing nations.

Dominion Diagnostics Offering COVID-19 Serology Antibody Testing

Retrieved on: 
Wednesday, June 24, 2020
Branches of biology, Glycoproteins, Antibodies, Immunology, Biology, Immunoglobulin M, Severe acute respiratory syndrome-related coronavirus, Medical laboratory, Immunoglobulin G

NORTH KINGSTOWN, R.I., June 24, 2020 /PRNewswire/ --Dominion Diagnostics is pleased to now offer COVID-19 serology antibody testing.

Key Points: 
  • NORTH KINGSTOWN, R.I., June 24, 2020 /PRNewswire/ --Dominion Diagnostics is pleased to now offer COVID-19 serology antibody testing.
  • Dominion Diagnostics utilizes the Siemens SARS-CoV-2 Total Antibody test to identify two antibodies, Immunoglobulin M (IgM) and Immunoglobulin G (IgG).
  • Dominion Diagnostics is a national medical laboratory providing clinical drug monitoring solutions, actionable clinical information, and innovative support solutions.
  • For over two decades, Dominion Diagnostics has been a leader in the industry working with addiction treatment centers, pain management centers, primary care centers, hospital systems and other specialties.For more information, please visit www.dominiondiagnostics.com .

Gencurix wins FDA EUA for COVID-19 Test Kit

Retrieved on: 
Wednesday, June 24, 2020
Natural sciences, Laboratory techniques, Branches of biology, Physical sciences, Molecular biology, Polymerase chain reaction, Reverse transcription polymerase chain reaction, Severe acute respiratory syndrome-related coronavirus, Assay, Severe acute respiratory syndrome

It is the second RT-PCR test that Gencurix has launched following the first test assay, GenePro COVID-19 Detection Test released last March.

Key Points: 
  • It is the second RT-PCR test that Gencurix has launched following the first test assay, GenePro COVID-19 Detection Test released last March.
  • With the FDA's EUA, Gencurix is now able to provide its COVID-19 detection tests the U.S. nationwide.
  • Gencurix's GenePro SARS-CoV-2 Test has the flexibility in the number of samples it can test simultaneously depending on the different PCR platforms.
  • Another important advantage of GenePro SARS-CoV-2 Test is the versatility of the RNA Extraction Kit.

Global WholeHealth Partners Submits “Made in the USA” COVID-19 Diagnostic Test EUA Application # EUA200181

Retrieved on: 
Wednesday, June 24, 2020
Medicine, Infectious diseases, Medical specialties, West African Ebola virus epidemic, Sexually transmitted diseases and infections, Ebola virus disease, RTT, Emergency Use Authorization, Severe acute respiratory syndrome-related coronavirus

SAN DIEGO,CA, June 24, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE --Global WholeHealth Partners Corp. (GWHP) submitted an Emergency Use Authorization (EUA) Application Submission Number EUA200181 for a "Made In the USA" COVID-19 Diagnostic Test for the Detection of Antibodies of SARS-CoV-2 on April 6 as mentioned in the 8Kfiling dated April 10, 2020.

Key Points: 
  • SAN DIEGO,CA, June 24, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE --Global WholeHealth Partners Corp. (GWHP) submitted an Emergency Use Authorization (EUA) Application Submission Number EUA200181 for a "Made In the USA" COVID-19 Diagnostic Test for the Detection of Antibodies of SARS-CoV-2 on April 6 as mentioned in the 8Kfiling dated April 10, 2020.
  • For international testing, which is not sold in the USA but has a Certificate of Exportability by the FDACertificate No.
  • 2260-11-2019,are tests like Rapid Ebola, Rapid Dengue Fever Antibody and Antigen, Rapid Tuberculosis (TB), Rapid Malaria, and many other rapid tests.
  • Call 1-877-568-GWHP (4947) to become a distributor or buy "Made In The USA" COVID 19 rapid test kits.

Novavax to Participate in H.C. Wainwright Fireside Chat Series

Retrieved on: 
Wednesday, June 24, 2020
Vaccines, Novavax, Viruses, Adjuvants, Health, Vaccine, Medicine, Severe acute respiratory syndrome-related coronavirus, H5N1 clinical trials, Ebola vaccine

Novavax recently initiated development of NVX-CoV2373, its vaccine candidate against SARS-CoV-2, the virus that causes COVID-19, with Phase 1 clinical trial results expected in July of 2020.

Key Points: 
  • Novavax recently initiated development of NVX-CoV2373, its vaccine candidate against SARS-CoV-2, the virus that causes COVID-19, with Phase 1 clinical trial results expected in July of 2020.
  • NanoFlu, its quadrivalent influenza nanoparticle vaccine, met all primary objectives in its pivotal Phase 3 clinical trial in older adults.
  • Both vaccine candidates incorporate Novavax proprietary saponin-based Matrix-M adjuvant in order to enhance the immune response and stimulate high levels of neutralizing antibodies.
  • Novavax is a leading innovator of recombinant vaccines; its proprietary recombinant technology platform combines the power and speed of genetic engineering to efficiently produce highly immunogenic nanoparticles in order to address urgent global health needs.

BriaCell Files Provisional Patent Application for Novel Treatment and Diagnosis of Coronavirus Disease

Retrieved on: 
Wednesday, June 24, 2020
Viruses, Animal virology, Coronaviridae, Zoonoses, Severe acute respiratory syndrome-related coronavirus, Coronavirus, Severe acute respiratory syndrome, Middle East respiratory syndrome, Middle East respiratory syndrome-related coronavirus, Orthocoronavirinae

The patent application, entitled MULTI-VALENT DECOY RECEPTORS FOR DIAGNOSIS AND/OR TREATMENT OF CORONAVIRUS INFECTION, describes a platform to generate multi-valent molecular constructs (decoy receptors) that have the potential to prevent coronaviruses including the SARS-CoV-2 virus (the virus that causes Coronavirus Disease 2019 (COVID-19)) from entering (infecting) healthy host cells.

Key Points: 
  • The patent application, entitled MULTI-VALENT DECOY RECEPTORS FOR DIAGNOSIS AND/OR TREATMENT OF CORONAVIRUS INFECTION, describes a platform to generate multi-valent molecular constructs (decoy receptors) that have the potential to prevent coronaviruses including the SARS-CoV-2 virus (the virus that causes Coronavirus Disease 2019 (COVID-19)) from entering (infecting) healthy host cells.
  • Multi-valent constructs described in the patent application are believed to have both therapeutic and diagnostic potential, the latter in the context of determining whether a patient has developed coronavirus-specific antibodies.
  • The Company cautions that these novel therapeutics are still under early-stage research and development and is not making any express or implied claims as to their success in treatment or commercial viability.
  • The patent application seeks protection for, among others, the design of new therapeutics and diagnostics and methods for their use.

INOVIO Receives $71 Million Contract From U.S. Department of Defense To Scale Up Manufacture of CELLECTRA® 3PSP Smart Device and Procurement of CELLECTRA® 2000 for COVID-19 DNA Vaccine

Retrieved on: 
Tuesday, June 23, 2020
Viruses, Branches of biology, Biology, Zoonoses, Vaccination, Gene delivery, Coronaviridae, In Saudi Arabia, Severe acute respiratory syndrome-related coronavirus, DNA vaccination, Vaccine, Severe acute respiratory syndrome

CELLECTRA3PSP is designed to deliver INO-4800 directly into the skin, where the vaccine prompts the body's immune system to drive a robust immune response.

Key Points: 
  • CELLECTRA3PSP is designed to deliver INO-4800 directly into the skin, where the vaccine prompts the body's immune system to drive a robust immune response.
  • Initial development of this next generation CELLECTRA3PSP smart device began in 2019 with$8.1 millionin funding from the medical arm of the U.S. Defense Threat Reduction Agency's Medical CBRN Defense Consortium.
  • INO-4800 is INOVIO's DNA vaccine candidate being developed to protect against the novel coronavirus SARS-CoV-2, which causes COVID-19.
  • INOVIO's DNA medicines deliver optimized plasmids directly into cells intradermally or intramuscularly using INOVIO's proprietary hand-held smart device called CELLECTRA.